"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 3 | 0 | 3 |
| 1997 | 2 | 1 | 3 |
| 1998 | 3 | 0 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 2 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 5 | 6 |
| 2006 | 6 | 2 | 8 |
| 2007 | 7 | 3 | 10 |
| 2008 | 1 | 5 | 6 |
| 2009 | 5 | 3 | 8 |
| 2010 | 7 | 6 | 13 |
| 2011 | 5 | 4 | 9 |
| 2012 | 7 | 9 | 16 |
| 2013 | 12 | 9 | 21 |
| 2014 | 14 | 4 | 18 |
| 2015 | 8 | 4 | 12 |
| 2016 | 16 | 5 | 21 |
| 2017 | 8 | 3 | 11 |
| 2018 | 10 | 5 | 15 |
| 2019 | 14 | 10 | 24 |
| 2020 | 4 | 6 | 10 |
| 2021 | 7 | 5 | 12 |
| 2022 | 1 | 14 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes Obes Metab. 2023 04; 25(4):965-974.
-
An Assessment of Clinical Continuous Glucose Monitoring Targets for Older and High-Risk People Living with Type 1 Diabetes. Diabetes Technol Ther. 2023 02; 25(2):108-115.
-
Late Afternoon Vigorous Exercise Increases Postmeal but Not Overnight Hypoglycemia in Adults with Type 1 Diabetes Managed with Automated Insulin Delivery. Diabetes Technol Ther. 2022 Dec; 24(12):873-880.
-
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina (Kaunas). 2022 Oct 17; 58(10).
-
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 10; 28(10):2083-2091.
-
Real-time continuous glucose monitoring improves glycemic control and reduces hypoglycemia: Real-world data. Prim Care Diabetes. 2022 Dec; 16(6):786-790.
-
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct; 28(10):923-1049.
-
Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Curr Med Res Opin. 2022 Nov; 38(11):1785-1795.
-
Efficacy of tirzepatide 5, 10 and 15?mg versus semaglutide 2?mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes Obes Metab. 2022 09; 24(9):1861-1868.
-
Upload and Review of Insulin Pump and Glucose Sensor Data by Adults with Type 1 Diabetes: A Clinic Audit. Diabetes Technol Ther. 2022 07; 24(7):531-534.